organization · Reporting owner
EcoR1 Capital, LLC
Disclosed activity across 20 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director · 10% owner | December 30, 2024 | January 02, 2025 |
| Aktis Oncology, Inc.AKTS · Entity 4711 | Director | January 12, 2026 | January 13, 2026 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | 10% owner | May 07, 2026 | May 11, 2026 |
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | 10% owner | January 06, 2023 | January 07, 2023 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | 10% owner | December 18, 2023 | December 27, 2023 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | September 19, 2023 | September 22, 2023 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | 10% owner | May 26, 2023 | June 05, 2023 |
| Zymeworks Inc.ZYME · Entity 4458 | Director · 10% owner | June 26, 2025 | June 27, 2025 |
| iTeos Therapeutics, Inc.ITOS · Entity 75965 | 10% owner | May 14, 2025 | May 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date December 30, 2024 · Filed January 02, 2025
Jointly reported with NODELMAN OLEG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,860,180 |
Reported balance
After 2024-12-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-12-30 · Purchase · Acquired 65,184 · Balance 7,860,180 F2: Qualified Fund purchased all of the securities in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.71 to $12.9552, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 3. F4: After this transaction, Qualified Fund held 7,382,058 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,873,448 |
Reported balance
After 2024-12-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-12-31 · Purchase · Acquired 13,268 · Balance 7,873,448 F5: Qualified Fund purchased all of the securities in this transaction. F6: After this transaction, Qualified Fund held 7,395,326 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,880,094 |
Reported balance
After 2025-01-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-01-02 · Purchase · Acquired 6,646 · Balance 7,880,094 F7: Qualified Fund purchased all of the securities in this transaction. F8: After this transaction, Qualified Fund held 7,401,972 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
F2: Qualified Fund purchased all of the securities in this transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.71 to $12.9552, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 3.
F4: After this transaction, Qualified Fund held 7,382,058 shares of the Issuer's Common Stock.
F5: Qualified Fund purchased all of the securities in this transaction.
F6: After this transaction, Qualified Fund held 7,395,326 shares of the Issuer's Common Stock.
F7: Qualified Fund purchased all of the securities in this transaction.
F8: After this transaction, Qualified Fund held 7,401,972 shares of the Issuer's Common Stock.
Aktis Oncology, Inc.
Report date January 12, 2026 · Filed January 13, 2026
Jointly reported with NODELMAN OLEG
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 2,270,879 |
Reported balance
After 2026-01-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-01-12 · Conversion · Acquired 2,270,879 · Balance 2,270,879 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 202,862 |
Reported balance
After 2026-01-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-01-12 · Conversion · Acquired 202,862 · Balance 202,862 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 128,506 |
Reported balance
After 2026-01-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-01-12 · Conversion · Acquired 128,506 · Balance 128,506 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 4,348,658 |
Reported balance
After 2026-01-12 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-01-12 · Purchase · Acquired 2,077,779 · Balance 4,348,658 F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 347,305 |
Reported balance
After 2026-01-12 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-01-12 · Purchase · Acquired 144,443 · Balance 347,305 F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-12 · Conversion · Disposed 9,913,810 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-12 · Conversion · Disposed 997,299 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-12 · Conversion · Disposed 488,891 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-01-12 · Conversion · Disposed 2,397,500 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee note | 0 |
Reported balance
After 2026-01-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-01-12 · Conversion · Disposed 102,500 · Balance 0 F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Class A Common StockSEC Table II · derivative / convertible security | IndirectSee note | 965,190 |
Reported balance
After 2026-01-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-01-12 · Conversion · Acquired 965,190 · Balance 965,190 F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
| Class A Common StockSEC Table II · derivative / convertible security | IndirectSee Note | 86,222 |
Reported balance
After 2026-01-12 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-01-12 · Conversion · Acquired 86,222 · Balance 86,222 F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date. F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date. F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock converted into shares of Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the initial public offering of the Issuer's Common Stock for no additional consideration. Each share was immediately exercisable and had no expiration date.
F2: These securities are held by EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 Capital, LLC ("EcoR1") may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
F3: These securities are held by EcoR1 Capital Fund, L.P. ("Capital Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
F4: These securities are held by EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to and general partner of the fund. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
F5: Each share of Class A Common Stock is convertible into one share of Common Stock at the election of the holder for no additional consideration, subject to a 4.99% beneficial ownership limitation. Each share is immediately exercisable and has no expiration date.
Atara Biotherapeutics, Inc.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 1,552,000 |
Reported balance
After 2026-05-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-07 · Purchase · Acquired 507,407 · Balance 1,552,000 F2: Qualified Fund purchased 474,780 of the shares puchased in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F4: After this transaction, Qualified Fund held 1,445,609 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controller owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The reporting persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controller owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The reporting persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund purchased 474,780 of the shares puchased in this transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4: After this transaction, Qualified Fund held 1,445,609 shares of the Issuer's Common Stock.
LENZ Therapeutics, Inc.
Report date January 06, 2023 · Filed January 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Notes 1 and 2 | 8,538,446 |
Reported balance
Holding disclosure · report date 2023-01-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 8,538,446 F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. F2: Qualified Fund directly holds 8,039,801 of the shares of Common Stock reported in this Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund directly holds 8,039,801 of the shares of Common Stock reported in this Form 3.
Mirati Therapeutics, Inc.
Report date December 18, 2023 · Filed December 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,396,979 |
Reported balance
Holding disclosure · report date 2023-12-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,396,979 F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1") and Oleg Nodelman. EcoR1 is the general partner and investment adviser of private funds (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself and Mr. Nodelman. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1") and Oleg Nodelman. EcoR1 is the general partner and investment adviser of private funds (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself and Mr. Nodelman. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
Nuvation Bio Inc.
Report date September 19, 2023 · Filed September 22, 2023 · Amendment
Jointly reported with NODELMAN OLEG, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Notes | 12,674,775 |
Last balance in matching sequence
After 2023-09-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-09-19 · Purchase · Acquired 5,143,000 · Balance 12,504,675 F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 2 · 2023-09-20 · Purchase · Acquired 117,100 · Balance 12,621,775 F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 3 · 2023-09-21 · Purchase · Acquired 53,000 · Balance 12,674,775 F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F2: Qualified Fund is the record holder of these securities.
F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023.
F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023.
F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023.
TScan Therapeutics, Inc.
Report date May 26, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | IndirectSee Notes 1 and 2 | 5,000,000 |
Reported balance
Holding disclosure · report date 2023-05-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,000,000 F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such ecurities except to the extent of their respective pecuniary interests therein. F2: Qualified Fund directly holds 4,640,415 of the shares of Voting Common Stock reported in this Form 3. |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such ecurities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund directly holds 4,640,415 of the shares of Voting Common Stock reported in this Form 3.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 22,970,388 |
Reported balance
After 2025-06-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-06-26 · Other · Acquired 5,086,480 · Balance 22,970,388 F2: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants. F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 22,970,388 |
Reported balance
After 2025-06-26 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-06-26 · Tax withholding · Disposed 41 · Balance 22,970,388 F4: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares. F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Pre-Funded Warrants (right to acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee note | 0 |
Reported balance
After 2025-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-26 · Other · Disposed 5,086,521 · Balance 0 F5: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction. F6: The pre-funded warrants did not have an expiration date. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund acquired 4,818,424 shares of Common Stock in connection with the exercise of the pre-funded warrants.
F3: After the transactions reported herein, Qualified Fund held 21,582,563 shares of the Issuer's Common Stock.
F4: On June 26, 2025,the reporting persons exercised pre-funded warrants to purchase 5,086,521 shares of the Issuer's Common Stock for $0.0001 per share. The reporting persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 41 of the warrant shares (including 38 warrant shares issuable to Qualified Fund) to pay the exercise price and issuing to the reporting persons the remaining 5,086,480 shares.
F5: Qualified Fund exercised 4,818,462 of the pre-funded warrants reported in this transaction.
F6: The pre-funded warrants did not have an expiration date.
iTeos Therapeutics, Inc.
Report date May 14, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 7,388,978 |
Reported balance
After 2025-05-14 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-14 · Purchase · Acquired 1,658,978 · Balance 7,388,978 F2: Qualified Fund purchased 1,555,127 of the shares purchased in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.35 to $7.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F4: After this transaction, Qualified Fund held 6,926,788 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 10,688,978 |
Reported balance
After 2025-05-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-05-15 · Purchase · Acquired 3,300,000 · Balance 10,688,978 F5: Qualified Fund purchased 3,093,422 of the shares purchased in this transaction. F6: After this transaction, Qualified Fund held 10,020,210 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund purchased 1,555,127 of the shares purchased in this transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.35 to $7.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4: After this transaction, Qualified Fund held 6,926,788 shares of the Issuer's Common Stock.
F5: Qualified Fund purchased 3,093,422 of the shares purchased in this transaction.
F6: After this transaction, Qualified Fund held 10,020,210 shares of the Issuer's Common Stock.
Past disclosures · reporting ended (11)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adaptimmune Therapeutics PLC
Report date July 28, 2025 · Filed July 30, 2025
Section 16 reporting ended · disclosed 2025-07-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 130,492,680 |
Reported balance
After 2025-07-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-07-28 · Sale · Disposed 33,931,740 · Balance 130,492,680 F1: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares. F3: The reporting persons sold 5,655,290 ADSs representing 33,931,740 Ordinary Shares. Qualified Fund sold 5,281,476 of those ADSs, representing 31,688,856 Ordinary Shares. F4: The price reported in Column 4 is the price per ADS sold by the reporting persons. This price is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.1086 to $0.1184, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in this footnote. F5: After this transaction, the reporting persons beneficially owned 21,748,780 ADSs, including 20,569,634 ADS held by Qualified Fund representing 123,417,804 Ordinary Shares. F2: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 127,805,220 |
Reported balance
After 2025-07-29 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-07-29 · Sale · Disposed 2,687,460 · Balance 127,805,220 F1: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares. F6: The reporting persons sold 447,910 ADSs representing 2,687,460 Ordinary Shares. Qualified Fund sold 418,303 of those ADSs, representing 2,509,818 Ordinary Shares. F7: The price reported in Column 4 is the price per ADS sold by the reporting persons. F8: After this transaction, the reporting persons beneficially owned 21,300,870 ADSs, including 20,151,331 ADSs held by Qualified Fund representing 120,907,986 Ordinary Shares. F2: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 100,371,882 |
Reported balance
After 2025-07-30 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-07-30 · Sale · Disposed 27,433,338 · Balance 100,371,882 F1: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares. F9: The reporting persons sold 4,572,223 ADSs representing 27,433,338 Ordinary Shares. Qualified Fund sold 4,270,000 of those ADSs, representing 25,620,000 Ordinary Shares. F7: The price reported in Column 4 is the price per ADS sold by the reporting persons. F10: After this transaction, the reporting persons beneficially owned 16,728,647 ADSs, including 15,881,331 ADSs held by Qualified Fund representing 95,287,986 Ordinary Shares. F2: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These Ordinary Shares are held through American Depositary Shares ("ADS") of the Issuer. Each ADS represents 6 Ordinary Shares.
F2: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F3: The reporting persons sold 5,655,290 ADSs representing 33,931,740 Ordinary Shares. Qualified Fund sold 5,281,476 of those ADSs, representing 31,688,856 Ordinary Shares.
F4: The price reported in Column 4 is the price per ADS sold by the reporting persons. This price is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.1086 to $0.1184, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in this footnote.
F5: After this transaction, the reporting persons beneficially owned 21,748,780 ADSs, including 20,569,634 ADS held by Qualified Fund representing 123,417,804 Ordinary Shares.
F6: The reporting persons sold 447,910 ADSs representing 2,687,460 Ordinary Shares. Qualified Fund sold 418,303 of those ADSs, representing 2,509,818 Ordinary Shares.
F7: The price reported in Column 4 is the price per ADS sold by the reporting persons.
F8: After this transaction, the reporting persons beneficially owned 21,300,870 ADSs, including 20,151,331 ADSs held by Qualified Fund representing 120,907,986 Ordinary Shares.
F9: The reporting persons sold 4,572,223 ADSs representing 27,433,338 Ordinary Shares. Qualified Fund sold 4,270,000 of those ADSs, representing 25,620,000 Ordinary Shares.
F10: After this transaction, the reporting persons beneficially owned 16,728,647 ADSs, including 15,881,331 ADSs held by Qualified Fund representing 95,287,986 Ordinary Shares.
Akouos, Inc.
Report date June 30, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Notes 2 and 3 | 1,975,984 |
Last balance in matching sequence
After 2020-06-30 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-06-30 · Conversion · Acquired 799,984 · Balance 799,984 F1: The Series B Convertible Preferred Stock converted into Common Stock on a 21.073-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. Qualified acquired 386,974 shares of Common Stock on such conversion, and Venture acquired 321,641 shares of Common Stock on such conversion. The Series B Convertible Preferred Stock had no expiration date. F2: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. (Qualified), EcoR1 Venture Opportunity Fund, L.P. (Venture) and Biotech Opportunity GP, LLC (Biotech). EcoR1 is the investment adviser of private funds, including Qualified and Venture (collectively, the Funds). Biotech is the general partner of Venture, and EcoR1 is the general partner of Qualified. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. EcoR1 is filing this report for itself, Mr. Nodelman, Qualified, Venture and Biotech. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F3: The Funds hold the securities reported herein directly for the benefit of their investors. Qualified holds 1,383,048 shares of Common Stock, and Venture holds 321,641 shares of Common Stock. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Biotech indirectly beneficially owns the securities held by Venture as the general partner of Venture. Mr. Nodelman indirectly beneficially owns the securities reported herein as the control person of EcoR1 and Biotech. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 2 · 2020-06-30 · Purchase · Acquired 1,176,000 · Balance 1,975,984 F4: Qualified purchased 996,074 shares of Common Stock in the transaction. F2: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. (Qualified), EcoR1 Venture Opportunity Fund, L.P. (Venture) and Biotech Opportunity GP, LLC (Biotech). EcoR1 is the investment adviser of private funds, including Qualified and Venture (collectively, the Funds). Biotech is the general partner of Venture, and EcoR1 is the general partner of Qualified. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. EcoR1 is filing this report for itself, Mr. Nodelman, Qualified, Venture and Biotech. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F3: The Funds hold the securities reported herein directly for the benefit of their investors. Qualified holds 1,383,048 shares of Common Stock, and Venture holds 321,641 shares of Common Stock. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Biotech indirectly beneficially owns the securities held by Venture as the general partner of Venture. Mr. Nodelman indirectly beneficially owns the securities reported herein as the control person of EcoR1 and Biotech. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Notes 2 and 3 | 0 |
Reported balance
After 2020-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-30 · Conversion · Disposed 16,858,076 · Balance 0 F1: The Series B Convertible Preferred Stock converted into Common Stock on a 21.073-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. Qualified acquired 386,974 shares of Common Stock on such conversion, and Venture acquired 321,641 shares of Common Stock on such conversion. The Series B Convertible Preferred Stock had no expiration date. F2: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. (Qualified), EcoR1 Venture Opportunity Fund, L.P. (Venture) and Biotech Opportunity GP, LLC (Biotech). EcoR1 is the investment adviser of private funds, including Qualified and Venture (collectively, the Funds). Biotech is the general partner of Venture, and EcoR1 is the general partner of Qualified. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. EcoR1 is filing this report for itself, Mr. Nodelman, Qualified, Venture and Biotech. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F3: The Funds hold the securities reported herein directly for the benefit of their investors. Qualified holds 1,383,048 shares of Common Stock, and Venture holds 321,641 shares of Common Stock. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Biotech indirectly beneficially owns the securities held by Venture as the general partner of Venture. Mr. Nodelman indirectly beneficially owns the securities reported herein as the control person of EcoR1 and Biotech. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Convertible Preferred Stock converted into Common Stock on a 21.073-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. Qualified acquired 386,974 shares of Common Stock on such conversion, and Venture acquired 321,641 shares of Common Stock on such conversion. The Series B Convertible Preferred Stock had no expiration date.
F2: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P. (Qualified), EcoR1 Venture Opportunity Fund, L.P. (Venture) and Biotech Opportunity GP, LLC (Biotech). EcoR1 is the investment adviser of private funds, including Qualified and Venture (collectively, the Funds). Biotech is the general partner of Venture, and EcoR1 is the general partner of Qualified. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. EcoR1 is filing this report for itself, Mr. Nodelman, Qualified, Venture and Biotech. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended.
F3: The Funds hold the securities reported herein directly for the benefit of their investors. Qualified holds 1,383,048 shares of Common Stock, and Venture holds 321,641 shares of Common Stock. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Biotech indirectly beneficially owns the securities held by Venture as the general partner of Venture. Mr. Nodelman indirectly beneficially owns the securities reported herein as the control person of EcoR1 and Biotech. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F4: Qualified purchased 996,074 shares of Common Stock in the transaction.
Corvus Pharmaceuticals, Inc.
Report date September 30, 2021 · Filed October 01, 2021
Section 16 reporting ended · disclosed 2021-10-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note 2 | 2,081,077 |
Reported balance
After 2021-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-09-30 · Sale · Disposed 3,000,000 · Balance 2,081,077 F1: EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") sold 2,643,300 shares of Common Stock in this transaction and held 1,803,513 shares of Common Stock following this transaction. F2: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 2 | 81,077 |
Reported balance
After 2021-10-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-10-01 · Sale · Disposed 2,000,000 · Balance 81,077 F3: Qualified Fund sold 1,760,600 shares of Common Stock in this transaction and held 42,913 shares of Common Stock following this transaction. F2: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") sold 2,643,300 shares of Common Stock in this transaction and held 1,803,513 shares of Common Stock following this transaction.
F2: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
F3: Qualified Fund sold 1,760,600 shares of Common Stock in this transaction and held 42,913 shares of Common Stock following this transaction.
First Tracks Biotherapeutics, Inc.
Report date April 20, 2026 · Filed April 22, 2026
Section 16 reporting ended · disclosed 2026-04-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 3,174,519 |
Reported balance
After 2026-04-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-04-20 · Sale · Acquired 4,705,575 · Balance 3,174,519 F2: The Funds sold these share in a private placement described in the Form 8K filed by the Issuer on April 20, 2026. F3: Qualified Fund sold 4,420,064 of the securities in this transaction. F4: After this transaction, Qualified Fund holds 2,981,908 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein.
F2: The Funds sold these share in a private placement described in the Form 8K filed by the Issuer on April 20, 2026.
F3: Qualified Fund sold 4,420,064 of the securities in this transaction.
F4: After this transaction, Qualified Fund holds 2,981,908 shares of the Issuer's Common Stock.
Mersana Therapeutics, Inc.
Report date December 19, 2024 · Filed December 24, 2024
Section 16 reporting ended · disclosed 2024-12-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 11,328,000 |
Reported balance
After 2024-12-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-12-19 · Other · Disposed 8,036,688 · Balance 11,328,000 F2: The Funds exchanged 8,036,688 shares of Common Stock for pre-funded warrants to acquire 8,036,688 shares of Common Stock F3: Qualified Fund disposed of 7,578,596 shares of Common Stock disposed of in this exchange F4: After this transaction, Qualified Fund owns 10,682,303 shares of Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Pre-Funded WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Note | 8,036,688 |
Reported balance
After 2024-12-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-19 · Other · Acquired 8,036,688 · Balance 8,036,688 F2: The Funds exchanged 8,036,688 shares of Common Stock for pre-funded warrants to acquire 8,036,688 shares of Common Stock F5: Qualified Fund acquired 7,578,596 of the pre-funded warrants acquired in this exchange. F6: The pre-funded warrants do not have an expiration date. F7: Each pre-funded warrant is exercisable to purchase one share of Common Stock, except that a holder of a pre-funded warrant will not be entitled to exercise any pre-funded warrant if, upon giving effect or immediately prior to such exercise, such exercise would result in (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) exceeding 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise, or (ii) the combined voting power of Company securities beneficially owned by such holder (together with its affiliates) exceeding 9.99% of the combined voting power of all Company securities outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. F8: After this transaction, Qualified Fund owned 7,578,596 of the pre-funded warrants. F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: The Funds exchanged 8,036,688 shares of Common Stock for pre-funded warrants to acquire 8,036,688 shares of Common Stock
F3: Qualified Fund disposed of 7,578,596 shares of Common Stock disposed of in this exchange
F4: After this transaction, Qualified Fund owns 10,682,303 shares of Common Stock.
F5: Qualified Fund acquired 7,578,596 of the pre-funded warrants acquired in this exchange.
F6: The pre-funded warrants do not have an expiration date.
F7: Each pre-funded warrant is exercisable to purchase one share of Common Stock, except that a holder of a pre-funded warrant will not be entitled to exercise any pre-funded warrant if, upon giving effect or immediately prior to such exercise, such exercise would result in (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) exceeding 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise, or (ii) the combined voting power of Company securities beneficially owned by such holder (together with its affiliates) exceeding 9.99% of the combined voting power of all Company securities outstanding immediately after giving effect to such exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants.
F8: After this transaction, Qualified Fund owned 7,578,596 of the pre-funded warrants.
Odonate Therapeutics, Inc.
Report date December 01, 2021 · Filed December 10, 2021
Section 16 reporting ended · disclosed 2021-12-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 5,701,669 |
Reported balance
After 2021-12-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-12-01 · Purchase · Acquired 185,941 · Balance 5,701,669 F2: These securities were transferred from another Fund managed by EcoR1 to Qualified Fund as part of a periodic rebalancing of the portfolios of the Funds. After this transaction, Qualified Fund held 5,185,698 shares of the Issuer's Common Stock, and the other fund held 515,971 shares. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 5,701,669 |
Reported balance
After 2021-12-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-12-01 · Sale · Disposed 185,941 · Balance 5,701,669 F2: These securities were transferred from another Fund managed by EcoR1 to Qualified Fund as part of a periodic rebalancing of the portfolios of the Funds. After this transaction, Qualified Fund held 5,185,698 shares of the Issuer's Common Stock, and the other fund held 515,971 shares. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 5,545,000 |
Reported balance
After 2021-12-09 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-12-09 · Sale · Disposed 156,669 · Balance 5,545,000 F3: Qualified Fund sold 142,491 of these shares. After this transaction, Qualified Fund held 5,043,207 shares of the Issuer's Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 545,000 |
Reported balance
After 2021-12-10 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-12-10 · Sale · Disposed 5,000,000 · Balance 545,000 F4: Qualified Fund sold 4,547,500 of these shares. After this transaction, Qualified Fund held 495,707 shares of the Issuer's Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 0 |
Reported balance
After 2021-12-10 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2021-12-10 · Sale · Disposed 545,000 · Balance 0 F5: Qualified Fund sold 495,707 of these shares. After this transaction, Qualified Fund held no shares of the Issuer's Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
F2: These securities were transferred from another Fund managed by EcoR1 to Qualified Fund as part of a periodic rebalancing of the portfolios of the Funds. After this transaction, Qualified Fund held 5,185,698 shares of the Issuer's Common Stock, and the other fund held 515,971 shares.
F3: Qualified Fund sold 142,491 of these shares. After this transaction, Qualified Fund held 5,043,207 shares of the Issuer's Common Stock.
F4: Qualified Fund sold 4,547,500 of these shares. After this transaction, Qualified Fund held 495,707 shares of the Issuer's Common Stock.
F5: Qualified Fund sold 495,707 of these shares. After this transaction, Qualified Fund held no shares of the Issuer's Common Stock.
PROTHENA CORP PUBLIC LTD CO
Report date May 02, 2025 · Filed May 06, 2025
Section 16 reporting ended · disclosed 2025-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 8,266,342 |
Reported balance
After 2025-05-02 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-02 · Sale · Disposed 3,317,938 · Balance 8,266,342 F2: Qualified Fund sold 3,097,619 of the shares sold in this transaction. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2715 to $9.1789, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the ranges set forth in this footnote and footnotes 6 and 9. F4: After this transaction, Qualified Fund held 7,750,234 shares of the Issuer's Common Stock. F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 7,288,649 |
Reported balance
After 2025-05-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-05-05 · Sale · Disposed 977,693 · Balance 7,288,649 F5: Qualified Fund sold 916,492 of the shares of sold in this transaction. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1097 to $8.1972, inclusive. F7: After this transaction, Qualified Fund held 6,833,742 shares of the Issuer's Common Stock F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Note | 5,304,596 |
Reported balance
After 2025-05-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-05-06 · Sale · Disposed 1,984,053 · Balance 5,304,596 F8: Qualified Fund sold 1,859,851 of the shares sold in this transaction. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.4637 to $8.5939, inclusive. F10: After this transaction, Qualified Fund held 4,973,891 of the Issuer's Ordinary Shares. F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting persons are EcoR1 Capital, LLC ("Ecor1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (the "Fund"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund sold 3,097,619 of the shares sold in this transaction.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2715 to $9.1789, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each seperate price within the ranges set forth in this footnote and footnotes 6 and 9.
F4: After this transaction, Qualified Fund held 7,750,234 shares of the Issuer's Common Stock.
F5: Qualified Fund sold 916,492 of the shares of sold in this transaction.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1097 to $8.1972, inclusive.
F7: After this transaction, Qualified Fund held 6,833,742 shares of the Issuer's Common Stock
F8: Qualified Fund sold 1,859,851 of the shares sold in this transaction.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.4637 to $8.5939, inclusive.
F10: After this transaction, Qualified Fund held 4,973,891 of the Issuer's Ordinary Shares.
Panacea Acquisition Corp. II
Report date April 28, 2023 · Filed May 02, 2023
Jointly reported with EcoR1 Panacea Holdings II, LLC, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC, NODELMAN OLEG
Section 16 reporting ended · disclosed 2023-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-04-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-04-28 · Disposition to issuer · Disposed 545,000 · Balance 0 F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023.
F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.
Surface Oncology, Inc.
Report date September 01, 2020 · Filed September 03, 2020
Section 16 reporting ended · disclosed 2020-09-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee note 1 | 4,701,081 |
Reported balance
After 2020-09-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-09-01 · Sale · Disposed 332,780 · Balance 4,701,081 F1: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. (Qualified). EcoR1 is the general partner and investment adviser of private funds, including Qualified (collectively, the Funds). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this report for itself, Mr. Nodelman and Qualified. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. F2: Qualified sold 281,132 shares of the securities sold in the transaction and holds 3,981,674 shares of such securities after the transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: The Filers are EcoR1 Capital, LLC (EcoR1), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. (Qualified). EcoR1 is the general partner and investment adviser of private funds, including Qualified (collectively, the Funds). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this report for itself, Mr. Nodelman and Qualified. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns the securities reported herein as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein.
F2: Qualified sold 281,132 shares of the securities sold in the transaction and holds 3,981,674 shares of such securities after the transaction.
Tango Therapeutics, Inc.
Report date November 06, 2024 · Filed November 09, 2024
Section 16 reporting ended · disclosed 2024-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note | 11,836,178 |
Reported balance
After 2024-11-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-11-06 · Sale · Disposed 1,494,558 · Balance 11,836,178 F2: Qualified Fund sold 1,406,529 of the shares sold in this transaction. F3: After this transaction, Qualified Fund held 11,156,852 shares of Issuer's Common Stock. F1: The filers are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Qualified Fund and Mr. Nodelman. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 11,773,860 |
Reported balance
After 2024-11-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-11-07 · Sale · Disposed 62,318 · Balance 11,773,860 F4: Qualified Fund sold 58,647 of the shares sold in this transaction. F5: After this transaction, Qualified Fund held 11,098,205 shares of Issuer's Common Stock. F1: The filers are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Qualified Fund and Mr. Nodelman. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim ownership of such securities except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Note | 10,630,736 |
Reported balance
After 2024-11-07 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-11-07 · Sale · Disposed 1,143,124 · Balance 10,630,736 F6: Qualified Fund sold 1,075,794 of the shares sold in this transaction. F7: After this transaction, Qualified Fund held 10,022,411 shares of Issuer's Common Stock. F1: The filers are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Qualified Fund and Mr. Nodelman. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim ownership of such securities except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The filers are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Qualified Fund and Mr. Nodelman. The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds. Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The filers disclaim ownership of such securities except to the extent of their respective pecuniary interests therein.
F2: Qualified Fund sold 1,406,529 of the shares sold in this transaction.
F3: After this transaction, Qualified Fund held 11,156,852 shares of Issuer's Common Stock.
F4: Qualified Fund sold 58,647 of the shares sold in this transaction.
F5: After this transaction, Qualified Fund held 11,098,205 shares of Issuer's Common Stock.
F6: Qualified Fund sold 1,075,794 of the shares sold in this transaction.
F7: After this transaction, Qualified Fund held 10,022,411 shares of Issuer's Common Stock.
Voyager Therapeutics, Inc.
Report date January 09, 2023 · Filed January 11, 2023
Section 16 reporting ended · disclosed 2023-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 4,297,907 |
Reported balance
After 2023-01-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-01-09 · Sale · Disposed 456,000 · Balance 4,297,907 F2: Qualified Fund sold 429,505 shares of the Common Stock sold in this transaction. F3: After this transaction, Qualified Fund directly owned 3,999,933 shares of Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests the |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 3,961,507 |
Reported balance
After 2023-01-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-01-10 · Sale · Disposed 336,400 · Balance 3,961,507 F4: Qualified Fund sold 268,985 shares of the Common Stock sold in this transaction. F5: After this transaction, Qualified Fund directly owned 3,730,948 shares of Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests the |
| Common StockSEC Table I · non-derivative | IndirectSee Note 1 | 3,851,507 |
Reported balance
After 2023-01-11 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-01-11 · Sale · Disposed 110,000 · Balance 3,851,507 F6: Qualified Fund sold 103,609 shares of the Common Stock sold in this transaction. F7: After this transaction, Qualified Fund directly owned 3,627,339 shares of Common Stock. F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests the |
Filing footnotes · ownership attribution and instrument terms
F1: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 may be deemed to indirectly beneficially own them as the investment adviser to the Funds, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests the
F2: Qualified Fund sold 429,505 shares of the Common Stock sold in this transaction.
F3: After this transaction, Qualified Fund directly owned 3,999,933 shares of Common Stock.
F4: Qualified Fund sold 268,985 shares of the Common Stock sold in this transaction.
F5: After this transaction, Qualified Fund directly owned 3,730,948 shares of Common Stock.
F6: Qualified Fund sold 103,609 shares of the Common Stock sold in this transaction.
F7: After this transaction, Qualified Fund directly owned 3,627,339 shares of Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2021 Filed Dec 10, 2021 23:50 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | SaleCommon Stock | 156,669 | $1.82 | $284,980.91 |
DisclosureSEC source: 0001567619-21-021902 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 5,545,000 F3 · shares: Qualified Fund sold 142,491 of these shares. After this transaction, Qualified Fund held 5,043,207 shares of the Issuer's Common Stock. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| December 01, 2021 Filed Dec 10, 2021 23:50 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | SaleCommon Stock | 185,941 | $1.66 | $308,662.06 |
DisclosureSEC source: 0001567619-21-021902 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 5,701,669 F2 · shares: These securities were transferred from another Fund managed by EcoR1 to Qualified Fund as part of a periodic rebalancing of the portfolios of the Funds. After this transaction, Qualified Fund held 5,185,698 shares of the Issuer's Common Stock, and the other fund held 515,971 shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| December 01, 2021 Filed Dec 10, 2021 23:50 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 185,941 | $1.66 | $308,662.06 |
DisclosureSEC source: 0001567619-21-021902 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 5,701,669 F2 · shares: These securities were transferred from another Fund managed by EcoR1 to Qualified Fund as part of a periodic rebalancing of the portfolios of the Funds. After this transaction, Qualified Fund held 5,185,698 shares of the Issuer's Common Stock, and the other fund held 515,971 shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds held these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owned them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owned them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 21,758 | $7.69 | $167,229.81 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 6 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 4 Disclosed balance after: 1,169,241 F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| November 24, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 163,268 | $7.69 | $1,254,861.52 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 5 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 3 Disclosed balance after: 7,361,675 F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 23:39 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | SaleCommon Stock | 2,000,000 | $4.96 | $9,928,800.00 |
DisclosureSEC source: 0001567619-21-017771 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 2 Disclosed balance after: 81,077 F3 · shares: Qualified Fund sold 1,760,600 shares of Common Stock in this transaction and held 42,913 shares of Common Stock following this transaction. F3 · balance_after: Qualified Fund sold 1,760,600 shares of Common Stock in this transaction and held 42,913 shares of Common Stock following this transaction. F2 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 23:39 UTC | Corvus Pharmaceuticals, Inc. CRVS · Entity 4839 | SaleCommon Stock | 3,000,000 | $5.04 | $15,131,100.00 |
DisclosureSEC source: 0001567619-21-017771 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 2 Disclosed balance after: 2,081,077 F1 · shares: EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") sold 2,643,300 shares of Common Stock in this transaction and held 1,803,513 shares of Common Stock following this transaction. F1 · balance_after: EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") sold 2,643,300 shares of Common Stock in this transaction and held 1,803,513 shares of Common Stock following this transaction. F2 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and Qualified Fund. EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 31, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 56,598 | $8.64 | $489,006.72 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 4 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 4 Disclosed balance after: 1,147,483 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| July 31, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 56,598 | $8.64 | $489,006.72 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 3 Disclosed balance after: 7,198,407 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | OtherCall Option (Right to Purchase) · Derivative | 2,500 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012482 · doc1.xml · derivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 0 Underlying: Ordinary Shares · 250,000 shares Expires 2021-06-18 F2 · kind: On June 18, 2021, the Filers exercised 2,500 call options to acquire 250,000 Ordinary Shares. Qualified Fund exercised 2,099 of those call options to acquire 209,900 Ordinary Shares. After this transaction, Qualified Fund owned 9,485,116 Ordinary Shares. F2 · shares: On June 18, 2021, the Filers exercised 2,500 call options to acquire 250,000 Ordinary Shares. Qualified Fund exercised 2,099 of those call options to acquire 209,900 Ordinary Shares. After this transaction, Qualified Fund owned 9,485,116 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | OtherOrdinary Shares | 250,000 | $30.00 | $7,500,000.00 |
DisclosureSEC source: 0001567619-21-012482 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 11,284,280 F2 · kind: On June 18, 2021, the Filers exercised 2,500 call options to acquire 250,000 Ordinary Shares. Qualified Fund exercised 2,099 of those call options to acquire 209,900 Ordinary Shares. After this transaction, Qualified Fund owned 9,485,116 Ordinary Shares. F2 · shares: On June 18, 2021, the Filers exercised 2,500 call options to acquire 250,000 Ordinary Shares. Qualified Fund exercised 2,099 of those call options to acquire 209,900 Ordinary Shares. After this transaction, Qualified Fund owned 9,485,116 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 04, 2021 Filed May 4, 2021 16:51 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 165,000 | $23.25 | $3,835,755.00 |
DisclosureSEC source: 0001567619-21-008992 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,520,424 F4 · shares: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,374,066 shares of the Issuer's Common Stock. F4 · balance_after: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,374,066 shares of the Issuer's Common Stock. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 03, 2021 Filed May 4, 2021 16:51 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 20,800 | $23.31 | $484,872.96 |
DisclosureSEC source: 0001567619-21-008992 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,355,424 F3 · shares: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,209,066 shares of the Issuer's Common Stock. F3 · balance_after: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,209,066 shares of the Issuer's Common Stock. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 30, 2021 Filed May 4, 2021 16:51 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 35,700 | $23.16 | $826,815.57 |
DisclosureSEC source: 0001567619-21-008992 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,334,624 F2 · shares: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,188,266 shares of the Issuer's Common Stock. F2 · balance_after: Qualified Fund purchased all of the securities in this transaction. After the transaction, Qualified Fund held 6,188,266 shares of the Issuer's Common Stock. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 27, 2021 18:23 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 33,800 | $23.82 | $805,088.96 |
DisclosureSEC source: 0001567619-21-008650 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,298,924 F2 · shares: Qualified Fund purchased all of the securities described in this transaction. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 18:23 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 13,900 | $23.80 | $330,858.92 |
DisclosureSEC source: 0001567619-21-008650 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,265,124 F2 · shares: Qualified Fund purchased all of the securities described in this transaction. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 18:23 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 99,600 | $23.54 | $2,344,285.20 |
DisclosureSEC source: 0001567619-21-008650 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,251,224 F2 · shares: Qualified Fund purchased all of the securities described in this transaction. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1 and a director of the Issuer. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| April 13, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 3,966 | $10.27 | $40,734.79 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 6 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 3 Disclosed balance after: 1,355,625 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| April 13, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 27,534 | $10.27 | $282,801.71 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 5 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 6,990,265 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 16,745 | $9.49 | $158,873.21 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 4 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 3 Disclosed balance after: 1,351,659 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 116,255 | $9.49 | $1,103,004.19 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 6,962,731 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 37,770 | $10.03 | $378,855.76 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 3 Disclosed balance after: 1,334,914 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 17:55 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 262,230 | $10.03 | $2,630,324.24 |
DisclosureSEC source: 0001567619-21-007976 · doc1.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 1 and 2 Disclosed balance after: 6,846,476 F1 · ownership.nature: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 15:10 UTC | Panacea Acquisition Corp. II PANA · Entity 114006 | PurchaseClass A ordinary shares | 545,000 | $10.00 | $5,450,000.00 |
DisclosureSEC source: 0001213900-21-021365 · ownership.xml · nonDerivative · entry 1 EcoR1 Panacea Holdings II, LLC · CIK 0001842055 · Director · 10% owner NODELMAN OLEG · CIK 0001454385 · Director · CEO and Chairman of the Board EcoR1 Capital Fund, L.P. · CIK 0001567938 · Director · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Director · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Director · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · Director · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,000 F1 · ownership.direct: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| March 31, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | SaleClass A Common Stock | 151,544 | $10.45 | $1,583,634.80 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 2 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 4 Disclosed balance after: 1,145,600 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4 · ownership.nature: Capital Fund is the record holder of these securities. Read SEC document |
| March 31, 2021 Filed Nov 30, 2021 18:07 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | PurchaseClass A Common Stock | 151,544 | $10.45 | $1,583,634.80 |
DisclosureSEC source: 0001567619-21-021329 · doc1.xml · nonDerivative · entry 1 NODELMAN OLEG · CIK 0001454385 · Director EcoR1 Capital, LLC · CIK 0001587114 · Affiliate of Director EcoR1 Capital Fund, L.P. · CIK 0001567938 · Affiliate of Director EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · Affiliate of Director EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · Affiliate of Director Biotech Opportunity GP, LLC · CIK 0001816370 · Affiliate of Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Notes 2 and 3 Disclosed balance after: 6,735,790 F1 · kind: EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds. F2 · ownership.nature: EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F3 · ownership.nature: Qualified Fund is the record holder of these securities. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 15:14 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares | 875,000 | $20.75 | $18,156,250.00 |
DisclosureSEC source: 0001567619-21-006927 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 11,034,280 F2 · shares: Qualified Fund purchased 746,500 of the Ordinary Shares purchased in this transaction. After this transaction, Qualified Fund owned 9,275,216 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 22:53 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 531,000 | $18.70 | $9,928,425.60 |
DisclosureSEC source: 0001567619-21-006040 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 7,151,624 F3 · shares: Qualified Fund purchased 445,987 shares of the Common Stock purchased in this transaction. After this transaction, Qualified Fund held 6,005,266 shares of Common Stock. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 22:53 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 2,777,800 | $18.97 | $52,694,310.44 |
DisclosureSEC source: 0001567619-21-006040 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 6,620,624 F2 · shares: Qualified Fund purchased 2,333,073 shares of the Common Stock purchased in this transaction. After this transaction, Qualified Fund held 5,559,279 shares of Common Stock. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 23:00 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares | 10,800 | $22.02 | $237,866.76 |
DisclosureSEC source: 0001567619-21-004963 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 10,159,280 F3 · shares: Qualified Fund purchased 9,067 of the Ordinary Shares purchased in this transaction. After this transaction, Qualified Fund owned 8,528,716 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:58 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | PurchaseCommon Stock | 29,500 | $25.48 | $751,657.05 |
DisclosureSEC source: 0001567619-21-004961 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 3,842,824 F2 · shares: Qualified Fund purchased 13,862 shares of the Common Stock purchased in this transaction. After this transaction, Qualified Fund owned 3,226,206 shares of Common Stock. F1 · ownership.nature: The filing persons (the "Filers" are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the investment adviser and general partner of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 23:00 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares | 44,400 | $21.05 | $934,517.88 |
DisclosureSEC source: 0001567619-21-004963 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 10,148,480 F2 · shares: Qualified Fund purchased 37,274 of the Ordinary Shares purchased in this transaction. After this transaction, Qualified Fund owned 8,519,649 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:24 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares | 44,100 | $3.68 | $162,102.78 |
DisclosureSEC source: 0001567619-21-004588 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 10,104,080 F2 · shares: 37,022 of the Ordinary Shares purchased in this transaction were purchased by Qualified Fund. After this transaction, Qualified Fund owned 8,482,375 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 20:57 UTC Amendment | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares | 44,100 | $23.65 | $1,043,075.25 |
DisclosureSEC source: 0001567619-21-004660 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 10,104,080 F2 · shares: 37,022 of the Ordinary Shares purchased in this transaction were purchased by Qualified Fund. After this transaction, Qualified Fund owned 8,482,375 Ordinary Shares. F3 · price: The Filers are filing this amendment to correct the price at which the Ordinary Shares were purchased. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 4 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 00:14 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseCall Option · Derivative | 2,500 | $3.68 Strike: $30.00 | $9,189.50 |
DisclosureSEC source: 0001567619-21-004320 · doc1.xml · derivative · entry 5 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 2,500 Underlying: Ordinary Shares · 250,000 shares Expires 2021-06-30 F6 · shares: 2,099 of the options purchased in this transaction were purchased by Qualified Fund. After this transaction, Qualified Fund owned 2,099 options to acquire 209,900 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 00:14 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares | 198,840 | $23.46 | $4,665,541.99 |
DisclosureSEC source: 0001567619-21-004320 · doc1.xml · nonDerivative · entry 4 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 10,059,980 F5 · shares: 166,926 of the Ordinary Shares purchased in this transaction were purchased by Qualified Fund. After this transaction, Qualified Fund owned 8,445,353 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 17, 2021 Filed Feb 26, 2021 21:09 UTC Amendment | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseCall Option · Derivative | 2,500 | $3.68 Strike: $30.00 | $9,189.50 |
DisclosureSEC source: 0001567619-21-005004 · doc1.xml · derivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 2,500 Underlying: Ordinary Shares · 250,000 shares Expires 2021-06-18 F2 · shares: 2,099 of the options purchased in this transaction were purchased by Qualified Fund. After this transaction, Qualified Fund owned 2,099 options to acquire 209,900 Ordinary Shares. F3 · derivative.expiration_date: The Filers are filing this amendment to correct the expiration date of the options, which was reported as 6/30/2021 in the Form 4 filed on 2/17/2021. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 00:14 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares | 89,200 | $22.78 | $2,031,967.08 |
DisclosureSEC source: 0001567619-21-004320 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 9,861,140 F4 · shares: 80,040 of the Ordinary Shares purchased in this transaction were purchased by Qualified Fund. After this transaction, Qualified Fund owned 8,278,427 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:14 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares | 282,800 | $20.08 | $5,678,510.88 |
DisclosureSEC source: 0001567619-21-004320 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 9,771,940 F3 · shares: All of the Ordinary Shares purchased in this transaction were purchased by Qualified Fund. After this transaction, Qualified Fund owned 8,198,387 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:14 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares | 62,500 | $20.50 | $1,281,250.00 |
DisclosureSEC source: 0001567619-21-004320 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital, LLC · CIK 0001587114 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1 Disclosed balance after: 9,489,140 F2 · shares: All of the Ordinary Shares purchased in this transaction were purchased by Qualified Fund. After this transaction, Qualified Fund owned 7,915,587 Ordinary Shares. F1 · ownership.nature: The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantWarrant (Right to Buy) · Derivative | 131,333 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 12 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 131,333 Underlying: Class A Common Stock · 131,333 shares Expires not disclosed F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F9 · derivative.expiration_date: 5:00 p.m., New York City time, on February 10, 2026. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantWarrant (Right to Buy) · Derivative | 702,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 11 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 702,000 Underlying: Class A Common Stock · 702,000 shares Expires not disclosed F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F9 · derivative.expiration_date: 5:00 p.m., New York City time, on February 10, 2026. F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantWarrant (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 10 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Liability Company Disclosed balance after: 130,000 Underlying: Class A Common Stock · 130,000 shares Expires not disclosed F10 · price: Warrants included in units purchased in a private placement by EcoR1 Panacea Holdings, LLC for $10.00 per unit in connection with Panacea's initial public offering. Each unit consisted of one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. Upon the closing of the Business Combination, the warrants may be deemed to be derivative securities for purposes of Section 16. F9 · derivative.expiration_date: 5:00 p.m., New York City time, on February 10, 2026. F2 · ownership.nature: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | ConversionClass B Common Stock · Derivative | 2,775,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · derivative · entry 9 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Liability Company Disclosed balance after: 0 Underlying: Class A Common Stock · 2,775,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock owned prior to the Business Combination (as defined below) was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of EcoR1 Panacea Holdings, LLC (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. F2 · ownership.nature: EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC but each (other than EcoR1 Panacea Holdings, LLC) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 2,200,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 8 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 2,200,627 F7 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). F8 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Venture Opportunity Fund, LP, which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 515,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 7 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 1,297,144 F7 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 2,365,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 6 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 6,584,246 F7 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea, Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (such transaction, the "Business Combination"). F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 387,265 | $10.00 | $3,872,650.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 5 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 781,265 F6 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination (as defined below), an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 2,112,735 | $10.00 | $21,127,350.00 |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 4 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 4,218,735 F6 · price: Acquired pursuant to one of a number of subscription agreements that Panacea entered into with various investors pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination (as defined below), an aggregate of 47,655,000 shares of Class A Common Stock at a price of $10.00 per share. F4 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund Qualified, L.P., which is the record owner of these securities. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 20:59 UTC | Nuvation Bio Inc. NUVB · Entity 4384 | GrantClass A Common Stock | 394,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-010503 · doc4.xml · nonDerivative · entry 3 NODELMAN OLEG · CIK 0001454385 · Director · 10% owner EcoR1 Panacea Holdings, LLC · CIK 0001816134 · 10% owner EcoR1 Capital Fund, L.P. · CIK 0001567938 · 10% owner EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner EcoR1 Venture Opportunity Fund, LP · CIK 0001778011 · 10% owner EcoR1 Capital, LLC · CIK 0001587114 · 10% owner Biotech Opportunity GP, LLC · CIK 0001816370 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 394,000 F3 · price: Acquired immediately prior to the closing of the Business Combination pursuant to the forward purchase agreement entered into with Panacea Acquisition Corp. ("Panacea") at the time of its initial public offering for a purchase price of $10.00 per one share of Class A common stock and one-third of one warrant to purchase one share of Class A common stock. F5 · ownership.nature: Oleg Nodelman is the manager of EcoR1 Capital Fund, L.P. , which is the owner of record of these securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.